eligibility_summary
Eligible: ≥19 with biopsy-proven relapsed/progressive DLBCL-spectrum (incl. HGBCL, PMBCL, FL3B, or transformed), meeting liso-cel indication, imaging disease with a radiation-safe site, ECOG 0–2, adequate organs for CAR T, consent. Exclude: unsafe for RT, primary CNS lymphoma (secondary CNS with systemic allowed), need high-dose MTX, active 2nd malignancy (specified exceptions), pregnant/nursing, noncompliance risks, inadequate for lymphodepletion, lymphoma therapy <14 d before apheresis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm trial evaluating low-dose external beam radiation as bridging to lisocabtagene maraleucel (liso-cel) in relapsed/refractory B‑cell NHL. Interventions: • Bridging radiation: 2 Gy ×2 (DNA damage/debulking, potential immunomodulation to enhance CAR‑T trafficking/antigen presentation). Optional post-infusion RT up to 32 Gy. • Liso‑cel: autologous CD19‑directed CAR T‑cell therapy (biologic cell therapy, CAR with 4‑1BB costimulation/CD3ζ) that recognizes CD19 on malignant B cells and induces cytotoxic killing and cytokine-mediated clearance. • Lymphodepletion: fludarabine (antimetabolite) and cyclophosphamide (alkylating agent) to reduce host lymphocytes and promote CAR‑T expansion. Targets: CD19+ malignant B cells, irradiated tumor sites, immune microenvironment/lymphocyte compartment to optimize CAR‑T activity.